Reduced lipid, liquid, and limbal vascularization.
Gary N
GN
Foulks
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions; D015352:Dry Eye Syndromes / Q000139:chemically induced; D049690:History, Ancient; D006801:Humans; D007765:Lacrimal Apparatus / Q000187:drug effects; D016850:Limbus Corneae / Q000098:blood supply*; D050356:Lipid Metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009885:Ophthalmology / Q000266:history*; D013666:Tears / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A